文献速递胸部肿瘤头颈与中枢神经肿瘤

立体定向放射外科对比全脑放疗治疗小细胞肺癌颅内转移性疾病:系统综述与Meta分析

Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis.
PubMed 文献 · Lancet Oncol · 2022-05-26

该系统综述与Meta分析检索至2022年3月23日的文献,纳入31项研究(7项进入Meta分析),比较立体定向放射外科(SRS)与全脑放疗(WBRT)治疗小细胞肺癌颅内转移性疾病的总生存。SRS后总生存优于WBRT(含或不含SRS推量)及单独WBRT,但与WBRT联合SRS推量相比无显著差异;单臂研究汇总中位总生存为8.99个月。

要点

  • SRS后总生存优于WBRT(含或不含SRS推量),HR 0.85(95%CI 0.75-0.97)。
  • SRS后总生存优于单独WBRT,HR 0.77(95%CI 0.72-0.83)。
  • SRS与WBRT联合SRS推量相比总生存无显著差异,HR 1.17(95%CI 0.78-1.75)。

核心结论

  • 结果提示,在小细胞肺癌颅内转移性疾病患者中,SRS与WBRT治疗后的生存结局相当。
  • 未来前瞻性研究应关注肿瘤负荷以及WBRT与SRS治疗患者之间局部和远处颅内进展的差异。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、Embase、CENTRAL及灰色文献中自建库至2022年3月23日发表的英文对照试验和队列研究。
  • 共识别3823条记录,31项符合纳入标准,其中7项纳入Meta分析。
  • 主要结局为总生存,比较SRS与WBRT(含或不含SRS推量)的研究采用随机效应Meta分析汇总风险比(HR),单臂SRS研究采用中位数。
  • 研究注册于Open Science Framework(DOI 10.17605/OSF.IO/8M4HC)和PROSPERO(CRD42021258197)。

主要发现

  • SRS后总生存长于WBRT(含或不含SRS推量),HR 0.85(95%CI 0.75-0.97;7项研究;18130例患者)。
  • SRS后总生存长于单独WBRT,HR 0.77(95%CI 0.72-0.83;7项研究;16961例患者)。
  • SRS与WBRT联合SRS推量相比总生存无显著差异,HR 1.17(95%CI 0.78-1.75;4项研究;1167例患者)。
  • 单臂研究中,SRS后汇总中位总生存为8.99个月(95%CI 7.86-10.16;14项研究;1682例患者)。
  • 所有对照研究汇总时,研究间异质性较大(I²=71.9%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有对照研究汇总时存在较大异质性(I²=71.9%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with small-cell lung cancer (SCLC) are at high risk for intracranial metastatic disease (IMD). Although stereotactic radiosurgery (SRS) has supplanted whole brain radiotherapy (WBRT) as first-line treatment for IMD in most solid cancers, WBRT remains first-line treatment for IMD in patients with SCLC. We aimed to evaluate the efficacy of SRS in comparison with WBRT and assess treatment outcomes following SRS. METHODS: In this systematic review and meta-analysis, we searched MEDLINE, Embase, CENTRAL, and grey literature sources for controlled trials and cohort studies published in English reporting on SRS for IMD treatment in patients with SCLC from inception to March 23, 2022. Studies were excluded that did not report on SRS for IMD secondary to SCLC. Summary data were extracted. The primary outcome was overall survival, presented as pooled hazard ratios (HR) through random-effects meta-analysis for studies comparing SRS with WBRT with or without SRS boost, and as medians for single-arm SRS studies. This study is registered with the Open Science Framework, DOI 10.17605/OSF.IO/8M4HC, and PROSPERO, CRD42021258197. FINDINGS: Of 3823 identified records, 31 were eligible for inclusion; seven were included in the meta-analysis. Overall survival following SRS was longer than following WBRT with or without SRS boost (HR 0·85; 95% CI 0·75-0·97; n=7 studies; n=18 130 patients), or WBRT alone (0·77; 0·72-0·83; n=7 studies; n=16 961 patients), but not WBRT plus SRS boost (1·17, 0·78-1·75; n=4 studies; n=1167 patients). Using single-arm studies, pooled median overall survival from SRS was 8·99 months (95% CI 7·86-10·16; n=14 studies; n=1682 patients). Between-study heterogeneity was considerable when pooled among all comparative studies (I2=71·9%). INTERPRETATION: These results suggest survival outcomes are equitable following treatment with SRS compared with WBRT in patients with SCLC and IMD. Future prospective studies should focus on tumour burden and differences in local and distant intracranial progression between WBRT-treated and SRS-treated patients with SCLC. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Gaebe K, Li AY, Park A, et al. Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. Lancet Oncol. 2022. PMID: 35644163. doi:10.1016/S1470-2045(22)00271-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。